Back to top
more

Arcus Biosciences (RCUS)

(Delayed Data from NYSE)

$17.11 USD

17.11
529,525

-0.10 (-0.58%)

Updated May 14, 2024 04:00 PM ET

After-Market: $17.10 -0.01 (-0.06%) 4:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Rise Y/Y

by Zacks Equity Research

Puma Biotechnology (PBYI) earnings and sales beat estimates in Q1. Stock rises in after-hours.

Apellis (APLS) Q1 Earnings Miss, Empaveli & Syfovre Fuel Growth

by Zacks Equity Research

Apellis Pharmaceuticals' (APLS) loss in the first quarter is wider than estimates. Empaveli and Syfovre boost product revenues for the company.

Zoetis (ZTS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Zoetis' (ZTS) first-quarter 2023 earnings beat estimates, while revenues miss the same. The company reiterates its financial guidance for 2023.

Amarin's (AMRN) Q1 Earnings Top, Vascepa Sales Fall

by Zacks Equity Research

Amarin's (AMRN) first-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.

Repligen (RGEN) Beats on Q1 Earnings, Lowers 2023 Guidance

by Zacks Equity Research

Repligen's (RGEN) first-quarter earnings and revenues beat estimates.

Earnings Preview: Arcus Biosciences, Inc. (RCUS) Q1 Earnings Expected to Decline

by Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

KALA Q4 Loss Wider Than Expected, Pipeline Remains in Focus

by Zacks Equity Research

Kala's Q4 earnings miss estimates. Its shares rise in pre-market trading on Mar 6.

Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top

by Zacks Equity Research

Puma Biotechnology's (PBYI) Q4 2022 loss is wider than estimates, Revenues beat the same.

Amarin's (AMRN) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Amarin Corporation's (AMRN) fourth-quarter 2022 earnings and revenues beat estimates; Vascepa sales decline.

Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 6.06% and 45.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Repligen's (RGEN) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Repligen (RGEN) reports encouraging fourth-quarter and full-year 2022 results, with sales and earnings beating estimates.

Alkermes (ALKS) Q4 Earnings & Sales Top Estimates, Stock Up

by Zacks Equity Research

Alkermes' (ALKS) earnings and sales beat estimates in the fourth quarter of 2022.

Biogen (BIIB) Beats Q4 Earnings & Sales Estimates, Stock Up

by Zacks Equity Research

Biogen (BIIB) beats fourth-quarter estimates for earnings and sales. Stock rises in pre-market.

Zacks.com featured highlights include Arcus Biosciences, Suzano and Arch Resources

by Zacks Equity Research

Arcus Biosciences, Suzano and Arch Resources are part of the Zacks Screen of the Week article.

Tirthankar Chakraborty headshot

Buy 3 Top Profitable Stocks Using Net Income Ratio

by Tirthankar Chakraborty

Arcus Biosciences (RCUS), Suzano (SUZ), and Arch Resources (ARCH) has been selected as the top picks with a high net income ratio.

CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors' focus will be on CRISPR Therapeutics' (CRSP) pipeline, specifically its lead candidate exa-cel, in its fourth-quarter earnings.

Vertex (VRTX) Beats on Q4 Earnings & Sales, '23 View Encouraging

by Zacks Equity Research

Vertex Pharmaceuticals' (VRTX) four-quarter 2022 earnings and sales beat estimates. VRTX also issues better-than-expected revenue guidance for 2023.

Will AbbVie's (ABBV) New Drugs Continue to Drive Q4 Earnings?

by Zacks Equity Research

AbbVie's (ABBV) fourth-quarter performance is expected to reflect the impact of strong demand for immunology and neuroscience products.

Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Vertex Pharmaceuticals' (VRTX) Q4 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates.

GSK Gears Up to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix and Juluca to drive fourth-quarter sales.

Pliant Therapeutics (PLRX) Surges 44% in A Week: Here's Why

by Zacks Equity Research

Shares of Pliant Therapeutics (PLRX) have been rising since management reported positive interim data from a mid-stage study evaluating a higher dose of its lead pipeline candidate in IPF patients.

Amarin Corporation (AMRN) Down 13% in One Week: Here's Why

by Zacks Equity Research

Shares of Amarin Corporation (AMRN) fell last week as the company's largest shareholder pressurizes the company to make changes to its board of directors.

Seagen's (SGEN) Tukysa Gets Accelerated FDA Nod for New Indication

by Zacks Equity Research

The FDA grants accelerated approval to Seagen's (SGEN) Tukysa in combination with trastuzumab for previously treated HER2-positive metastatic colorectal cancer.

Angion (ANGN) Down on Merger Agreement With Private Biotech

by Zacks Equity Research

Angion (ANGN) inks a definitive merger agreement with privately-held Elicio Therapeutics. The combined company's lead pipeline candidate will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors.

Roche (RHHBY) Gets EU Approval for Xofluza in New Patient Base

by Zacks Equity Research

The European Commission approves Roche's (RHHBY) Xofluza for treating uncomplicated influenza and post-exposure prophylaxis of influenza in children aged one year and above.